Peptide mapping plays a critical role in quality assurance of mAbs and is widely
applied for primary structure characterization. However, we have to understand
that peptide mapping is usually performed in a comparative manner, in which the
peptide map of a proposed mAb product is compared to that of a reference
product in a side-by-side experiment, which is extremely time consuming and
highly dependent on the reproducible sample preparation. An in-depth peptide
mapping method is thus required to characterize peptide sequences of mAbs.
An emerging technique, and the focus of this report, is DIA mode on Q-TOF
mass spectrometry. DIA enables a genetic, unbiased approach for the MS/MS
data acquisition, in which all the ions in each individual MS/MS event are
fragmented without precursor ion isolation and all the fragment ions are
measured in a mixed spectrum, ideal for peptide sequencing .
In this study, we demonstrated an integrated DIA approach on LCMS-9030 QTOF
mass spectrometer for de novo peptide sequencing of mAbs.
- Content Type:
- Document Number:
- ASMS 2020 - MP 117
- Product Type:
- Liquid Chromatography Mass Spectrometry (LC-MS)
- Pharma & Biopharma, LCMS-9030 Q-TOF Mass Spectrometer
- File Name:
- File Size:
Question about this literature?